ATL transducer gets PMA

Article

ATL Ultrasound has received supplemental premarket approval (PMA) from the Food and Drug Administration to market a new scanhead, L12-5, for breast imaging applications on the company's HDI 3000 scanner. The transducer features a new design that improves

ATL Ultrasound has received supplemental premarket approval (PMA) from the Food and Drug Administration to market a new scanhead, L12-5, for breast imaging applications on the company's HDI 3000 scanner. The transducer features a new design that improves near-field focus and image quality, according to the Bothell, WA, vendor. ATL has also received PMAs for breast imaging applications with its Ultramark 9 HDI and HDI 3000 systems.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.